|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 259.70 CHF | +1.05% |
|
+0.82% | +1.64% |
| 05-15 | Foreign companies eye US expansion to lessen fallout from tariffs | RE |
| 05-15 | Roche: receives FDA approval for cancer drug | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions on site
| Capitalization | 208B 249B 223B 187B 348B 21,307B 389B 2,421B 950B 9,661B 934B 915B 36,164B | P/E ratio 2025 * |
14.2x | P/E ratio 2026 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise value | 219B 262B 235B 198B 367B 22,463B 410B 2,553B 1,002B 10,185B 985B 965B 38,126B | EV / Sales 2025 * |
3.47x | EV / Sales 2026 * | 3.25x |
| Free-Float |
87.84% | Yield 2025 * |
3.8% | Yield 2026 * | 3.9% |
More valuation ratios
* Estimated data
More news
Last Transcript: Roche Holding AG
More press releases
More news
| 1 day | +1.05% | ||
| 1 week | +0.82% | ||
| Current month | -3.56% | ||
| 1 month | +1.60% | ||
| 3 months | -11.76% | ||
| 6 months | +1.52% | ||
| Current year | +1.64% |
| 1 week | 246 |  | 265.1 |
| 1 month | 246 | | 274.6 |
| Current year | 231.9 | | 313.8 |
| 1 year | 226.5 | | 313.8 |
| 3 years | 212.9 | | 335.85 |
| 5 years | 212.9 | | 404.2 |
| 10 years | 206.35 | | 404.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2023-03-14 | |
Alan Hippe
DFI | Director of Finance/CFO | 58 | 2011-06-05 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 58 | 2025-02-09 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 67 | 1995-12-31 |
Severin Schwan
CHM | Chairman | 58 | 2023-03-14 |
| Director/Board Member | 72 | 2015-03-02 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 21 M€ | -0.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.05% | +0.82% | +9.53% | -19.44% | 248B | ||
| +3.50% | +3.11% | -1.64% | +151.29% | 680B | ||
| +1.15% | -1.87% | -2.14% | -15.37% | 364B | ||
| +1.29% | -0.31% | +10.58% | +18.89% | 325B | ||
| -1.81% | -4.00% | -52.78% | +13.93% | 283B | ||
| +1.25% | +0.62% | -2.03% | +4.64% | 213B | ||
| +1.85% | +0.88% | -14.70% | -1.51% | 212B | ||
| +1.68% | +0.12% | -42.02% | -18.22% | 191B | ||
| +1.15% | +2.46% | -12.82% | +11.03% | 146B | ||
| +1.02% | +2.47% | -20.29% | -55.53% | 130B | ||
| Average | +1.21% | +0.43% | -12.83% | +8.97% | 279.29B | |
| Weighted average by Cap. | +1.52% | +0.51% | -9.71% | +33.70% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 63.17B 75.47B 67.6B 56.86B 106B 6,467B 118B 735B 288B 2,932B 284B 278B 10,976B | 65.9B 78.74B 70.53B 59.32B 110B 6,746B 123B 767B 301B 3,059B 296B 290B 11,450B |
| Net income | 14.07B 16.81B 15.06B 12.66B 23.5B 1,440B 26.28B 164B 64.24B 653B 63.14B 61.84B 2,444B | 15.21B 18.18B 16.28B 13.69B 25.42B 1,557B 28.42B 177B 69.48B 706B 68.28B 66.88B 2,643B |
| Net Debt | 11.29B 13.49B 12.08B 10.16B 18.87B 1,156B 21.09B 131B 51.56B 524B 50.68B 49.64B 1,962B | 5.73B 6.85B 6.13B 5.16B 9.58B 587B 10.71B 66.68B 26.18B 266B 25.73B 25.2B 996B |
More financial data
* Estimated data
Employees
103,249
Sector
Pharmaceuticals
Calendar
05-27
- Investor Day
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-05-16 | 259.70 CHF | +1.05% | 1,706,043 |
| 25-05-15 | 257.00 CHF | +0.98% | 831,299 |
| 25-05-14 | 254.50 CHF | -1.74% | 1,233,370 |
| 25-05-13 | 259.00 CHF | -1.11% | 1,052,072 |
| 25-05-12 | 261.90 CHF | +1.67% | 2,082,326 |
Delayed Quote Swiss Exchange, May 16, 2025 at 11:31 am
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
259.70CHF
Average target price
302.63CHF
Spread / Average Target
+16.53%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition